Current Report Filing (8-k)
June 19 2018 - 5:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
June 7, 2018
OncoCyte
Corporation
(Exact
name of registrant as specified in its charter)
California
|
|
1-37648
|
|
27-1041563
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1010
Atlantic Avenue
Suite
102
Alameda,
California 94501
(Address
of principal executive offices)
(510)
775-0515
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may,”
“will,” “believes,” “plans,” “intends,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual
results to differ materially from the results anticipated in these forward-looking statements are contained in OncoCyte Corporation’s
Form 10 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and
other filings that OncoCyte may make with the SEC. Undue reliance should not be placed on these forward-looking statements which
speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required
by law, OncoCyte disclaims any intent or obligation to update these forward-looking statements.
References
to “OncoCyte,” “we” or “us” are references to OncoCyte Corporation
Section
5 - Corporate Governance and Management
Item
5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
Executive
Compensation
As
part of our cost reduction efforts, our Vice President—Marketing, Kristine Mechem, agreed to take sabbatical leave commencing
June 11, 2018. The initial sabbatical period will end on September 10, 2018, but may be extended by OncoCyte for up to an additional
three months. During the sabbatical period, Ms. Mechem will be treated as an employee on unpaid leave, meaning that she will be
entitled to participate in employee benefit plans but will not receive her salary other than for any available paid time off days
that she may elect to utilize. If OncoCyte elects to terminate Ms. Mechem’s employment during the sabbatical period, or
determines not to reinstate her salary after the sabbatical period, or if she declines to continue her sabbatical following OncoCyte’s
election to extend the sabbatical period, she will be entitled to the severance benefits provided by her employment agreement.
In
connection with Ms. Mechem’s agreement to take a sabbatical, she was granted options to purchase 50,000 shares of OncoCyte
common stock under our Employee Stock Option Plan (the “Plan”). The exercise price of the options is $2.85 per share,
the fair market value of OncoCyte common stock determined in accordance with the Plan. The options shall become exercisable upon
vesting. One half of the option will vest upon the filing of the Medicare dossier for a local coverage determination for our
DetermaVu™ lung cancer diagnostic test, and one half of the options will vest upon OncoCyte obtaining a Medicare local
coverage determination for DetermaVu™. Vesting is subject to Ms. Mechem’s continued service as an employee on the
applicable vesting date.
On
June 13, 2018, we entered into a memorandum of agreement with our Chief Financial Officer, Mitchell Levine, pursuant to which,
as part of our cost reduction efforts, Mr. Levine agreed to a temporary 10% salary reduction for the period June 10 to December
31, 2018. In the event of a termination of Mr. Levine’s employment that would entitle him to severance payments under his
employment agreement, the severance payments would be determined with reference to his base salary before the 10% salary reduction.
In
connection with Mr. Levine’s acceptance of a salary reduction, he was granted options to purchase 45,000 shares of OncoCyte
common stock under the Plan. The exercise price of the options is $2.55 per share, the fair market value of OncoCyte common stock
determined in accordance with the Plan. The options shall become exercisable upon vesting. One half of the option shall vest upon
the completion of a clinical validation study manuscript for DetermaVu™, and one-half of the options shall vest upon the
commencement of a clinical utility study of DetermaVu™.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOCYTE CORPORATION
|
|
|
|
Date:
June 19, 2018
|
By:
|
/
s/
William Annett
|
|
|
William
Annett
|
|
|
President
and Chief Executive Officer
|
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Apr 2023 to Apr 2024